First clinical trial of specific IKAChblocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation | Zendy

Steven Podd | Zendy; Nicholas Freemantle | Zendy; Stephen Furniss | Zendy; Neil Sulke | Zendy

Open Access

First clinical trial of specific I_KAChblocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation

Author(s) -

Steven Podd,

Nicholas Freemantle,

Stephen Furniss,

Neil Sulke

Publication year - 2015

Publication title -

ep europace

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.119

H-Index - 102

eISSN - 1532-2092

pISSN - 1099-5129

DOI - 10.1093/europace/euv263

Subject(s) - medicine , atrial fibrillation , paroxysmal atrial fibrillation , placebo , cardiology , qt interval , adverse effect , crossover study , implantable loop recorder , artificial cardiac pacemaker , anesthesia , alternative medicine , pathology

To assess the efficacy of BMS 914392 on atrial fibrillation (AF) burden reduction in 20 patients with pacemakers and paroxysmal atrial fibrillation (PAF). BMS 914392 is a potent, selective, oral inhibitor of the IKACh current and has been shown to suppress AF, whilst having no effect on the ventricular refractory period. This is the first efficacy study of BMS 914392 in patients with PAF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research